120 related articles for article (PubMed ID: 32020530)
21. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
23. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.
Deng Y; Sychterz C; Suttle AB; Dar MM; Bershas D; Negash K; Qian Y; Chen EP; Gorycki PD; Ho MY
Xenobiotica; 2013 May; 43(5):443-53. PubMed ID: 23548165
[TBL] [Abstract][Full Text] [Related]
24. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
25. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
26. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
27. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.
Sternberg CN; Motzer RJ; Hutson TE; Choueiri TK; Kollmannsberger C; Bjarnason GA; Paul Nathan ; Porta C; Grünwald V; Dezzani L; Han J; Tannir NM
Clin Genitourin Cancer; 2019 Dec; 17(6):425-435.e4. PubMed ID: 31601514
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic Analysis of a Hemodialyzed Patient Treated With Pazopanib.
Noda S; Hira D; Kageyama S; Jo F; Wada A; Yoshida T; Kawauchi A; Morita SY; Terada T
Clin Genitourin Cancer; 2016 Aug; 14(4):e453-6. PubMed ID: 27102404
[No Abstract] [Full Text] [Related]
29. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
Méndez-Vidal MJ; Molina Á; Anido U; Chirivella I; Etxaniz O; Fernández-Parra E; Guix M; Hernández C; Lambea J; Montesa Á; Pinto Á; Ros S; Gallardo E
BMC Pharmacol Toxicol; 2018 Nov; 19(1):77. PubMed ID: 30477570
[TBL] [Abstract][Full Text] [Related]
30. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
32. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
33. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
[TBL] [Abstract][Full Text] [Related]
34. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
35. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
36. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
[No Abstract] [Full Text] [Related]
37. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
Stein J; Milhem M; Vaena D
J Oncol Pharm Pract; 2020 Jan; 26(1):232-235. PubMed ID: 30961437
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
39. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
